# US 2023/0151400 A1 · Biosynthetic heparin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0151400 A1
- Document ID: US20230151400A1
- Status: Published application
- Kind: A1
- Application number: 18/099,749
- Filed: 2023-01-20
- Published: 2023-05-18
- Earliest claimed: 2016-09-07
- Assignees: Rensselaer Polytechnic Institute
- Applicants: Rensselaer Polytechnic Institute
- Inventors: Marc DOUAISI; Navdeep GROVER; Payel DATTA; Elena PASKALEVA; Lei LIN; Paul BRODFUEHRER; Trevor J. SIMMONS; Akihiro ONISHI; Makoto HIRAKANE; Li FU; Kevin LI; Robert J. LINHARDT; Jonathan DORDICK; Daisuke MORI
- Web page: https://patentgrep.com/patent/US20230151400A1

## CPC

- C12P 19/26: Preparation of nitrogen-containing carbohydrates
- C08B 37/003: {Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof}
- C08B 37/0069: {Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof}
- C08B 37/0075: {Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof}
- C08L 5/10: Heparin; Derivatives thereof
- C12N 9/10: Transferases (2.) (ribonucleases C12N9/22)
- C12N 9/13: {transferring sulfur containing groups (2.8)}
- C12P 19/04: Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
- C12Y 208/02: Sulfotransferases (2.8.2)
- C12Y 208/02001: Aryl sulfotransferase (2.8.2.1)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present disclosure relates to synthesis of heparin, which may be bioequivalent to porcine USP Heparin Sodium. The synthesis may involve three intermediates starting from heparosan.

## Claims

### Claim 1

A glycosaminoglycan comprising 31-73% of NS2S6S disaccharide group; 6-40% of NS6S disaccharide group; 0-27% of NS2S group and 1-22% of NS group.

### Claim 2 (depends on 1)

The glycosaminoglycan of claim 1, comprising 36-70% of NS2S6S disaccharide group and 6-32% of NS6S disaccharide group.

### Claim 3 (depends on 1)

The glycosaminoglycan of claim 1, comprising 40-67% of NS2S6S disaccharide group and 6-26% of NS6S disaccharide group.

### Claim 4 (depends on 1)

The glycosaminoglycan of claim 1, comprising 43-64% of NS2S6S disaccharide group and 6-22% of NS6S disaccharide group.

### Claim 5 (depends on 1)

The glycosaminoglycan of claim 1 comprising 12-27% of NS2S group and 1-17% of NS group.

### Claim 6 (depends on 1)

The glycosaminoglycan of claim 1, having a weight average molecular weight properties appropriate to form a final heparin product of 15,000-19,000 Da, the percentage of heparin chains with a molecular weight of greater than 24,000 Da being not more than 20% of the total, and the ratio of chains between molecular weights of 8,000 to16,000 Da to the percentage of chains with molecular weights of 16,000 to 24,000 Da being not less than 1.0.

### Claim 7

A method for producing a biosynthetic heparin, comprising;
(a) obtaining a glycosaminoglycan comprising 31-73% of NS2S6S disaccharide group, 6-40% of NS6S disaccharide group, 0-27% of NS2S group and 1-22% of NS group;
(b) treating the glycosaminoglycan with an enzyme, which is 3-O-sulfotransferase isoform 1 (3OST-1), in the presence of a sulfate donor.
to produce a biosynthetic heparin batch.

### Claim 8 (depends on 7)

The method of claim 7, wherein in step (b) sufficient glucosamine residues are converted to 3-O-sulfoglucosamine residues so that the produced batch has anti-Xa and anti-IIa activities of no less than 180 units/mg and an anti-Xa/anti-IIa ratio of 0.85-1.15.

### Claim 9 (depends on 8)

The method of claim 8, wherein the anti-Xa/anti-IIa ratio is 0.9-1.1.

### Claim 10 (depends on 7)

The method of claims 7, wherein the sulfate donor comprises PAPS.

### Claim 11 (depends on 10)

The method of claim 10, wherein the PAPS is in a solution.

### Claim 12 (depends on 7)

The method of claims 7, wherein the sulfate donor comprises PAPS and PNPS.

### Claim 13 (depends on 7)

The method of claims 7, wherein said treatment is performed in the presence of a recycling system comprising PAPS, PNPS and a catalyst.

### Claim 14 (depends on 13)

The method of claim 13, wherein the catalyst is aryl sulfotransferase IV (AST-IV).

### Claim 15 (depends on 7)

The method of claims 7, wherein the enzyme is in solution.

### Claim 16 (depends on 7)

The method of claims 7, wherein the enzyme is immobilized.
